Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$24.46 - $40.4 $54,227 - $89,566
-2,217 Reduced 16.66%
11,090 $295,000
Q1 2024

Apr 29, 2024

BUY
$36.38 - $52.31 $17,680 - $25,422
486 Added 3.79%
13,307 $549,000
Q4 2023

Feb 07, 2024

BUY
$14.19 - $42.33 $1,830 - $5,460
129 Added 1.02%
12,821 $527,000
Q3 2023

Nov 02, 2023

SELL
$19.64 - $28.21 $5,401 - $7,757
-275 Reduced 2.12%
12,692 $249,000
Q2 2023

Aug 07, 2023

SELL
$21.73 - $31.43 $260 - $377
-12 Reduced 0.09%
12,967 $321,000
Q1 2023

May 09, 2023

SELL
$26.15 - $37.26 $21,887 - $31,186
-837 Reduced 6.06%
12,979 $354,000
Q4 2022

Feb 09, 2023

BUY
$32.47 - $57.24 $19,482 - $34,344
600 Added 4.54%
13,816 $472,000
Q3 2022

Nov 09, 2022

SELL
$41.87 - $57.99 $11,974 - $16,585
-286 Reduced 2.12%
13,216 $588,000
Q2 2022

Aug 10, 2022

SELL
$36.01 - $74.24 $27,295 - $56,273
-758 Reduced 5.32%
13,502 $569,000
Q1 2022

May 09, 2022

BUY
$60.27 - $81.57 $23,746 - $32,138
394 Added 2.84%
14,260 $960,000
Q4 2021

Feb 09, 2022

SELL
$65.85 - $96.21 $4.57 Million - $6.68 Million
-69,390 Reduced 83.35%
13,866 $1.14 Million
Q3 2021

Nov 09, 2021

BUY
$73.2 - $107.87 $168,360 - $248,101
2,300 Added 2.84%
83,256 $6.84 Million
Q2 2021

Aug 10, 2021

BUY
$60.45 - $84.26 $1.16 Million - $1.62 Million
19,168 Added 31.02%
80,956 $6.23 Million
Q1 2021

May 10, 2021

BUY
$58.19 - $91.37 $177,537 - $278,769
3,051 Added 5.19%
61,788 $4.08 Million
Q4 2020

Feb 08, 2021

BUY
$20.19 - $84.93 $388,657 - $1.63 Million
19,250 Added 48.75%
58,737 $4.99 Million
Q3 2020

Nov 06, 2020

BUY
$22.99 - $36.34 $333,768 - $527,584
14,518 Added 58.14%
39,487 $932,000
Q2 2020

Aug 05, 2020

BUY
$29.88 - $56.74 $592,639 - $1.13 Million
19,834 Added 386.25%
24,969 $837,000
Q1 2020

May 12, 2020

BUY
$33.0 - $54.5 $7,029 - $11,608
213 Added 4.33%
5,135 $207,000
Q4 2019

Feb 05, 2020

BUY
$15.39 - $44.38 $75,749 - $218,438
4,922 New
4,922 $202,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.